• Emerging Lymphoma Therapies at AACR 2023: Promising Results in CD19 Immunotherapy, CAR-T Cells, and Dual-Specific Antibodies

    The 2023 American Association for Cancer Research (AACR) Annual Meeting was held in Orlando, USA, from April 14 to 19, 2023. Every year, the AACR Congress reports numerous clinical, basic, and translational studies on cancer, especially innovative therapies in the preliminary phase I/II research stages. At this year’s AACR conference, three clinical trials were reported…

  • Dr. Yao Zhu talks to Dr. Nguyen: Advances in Radiotherapy and Surgical Treatment of Prostate Cancer at ASCO-GU 2023

    The 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU 2023) has concluded. During this conference, several studies related to early-stage/ localized prostate cancer radiotherapy or surgical treatment were presented as oral reports. Among them, the FORMULA-509 study presented by Dr. Paul L. Nguyen of the Dana-Farber Cancer Institute at Harvard Medical School…

  • Dr. Ming Zhao: Key Clinical Research in Hepatocellular Carcinoma｜Highlights from APPLE 2023

    From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) was held in Seoul, South Korea. Hepatocellular carcinoma (HCC) experts from around the world gathered to rekindle academic discussions on HCC’s basics, clinical aspects, research, and technology offline. The conference featured the latest research results from over a thousand…

  • Interview with Minggui Wang at ECCMID 2023

    The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) recently took place in Copenhagen, Denmark, drawing attention as one of the first major in-person events since the easing of the COVID-19 pandemic. The event, a hallmark in the world of infectious diseases and clinical microbiology, attracted numerous participants, among whom was Dr. Minggui…

  • Dr. Michelle Seif: CAR-T Therapy’s Potential in Treating Fungal Infections丨ECCMID 2023

    At the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023), the prospect of utilizing Chimeric Antigen Receptor T-cells (CAR-T) for medical treatments has emerged as a promising avenue, especially in the realm of infectious diseases. Notably, Dr. Michelle Seif from the University Hospital Würzburg, Germany, has presented new findings that expand upon…

  • Dr. José Luis Del Pozo: The Fight Against Gram-Positive Bacterial Infections丨ECCMID 2023

    In an era where antibiotic-resistant infections like MRSA are on the rise, healthcare professionals are constantly in search of potent drugs to combat these pathogens. The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) presented an opportunity to explore advancements in this area. One of the notable voices at this congress was…

  • Antimicrobial Susceptibility Testing: Insights from EUCAST Pioneer, Dr. Gunnar Kahlmeter丨ECCMID 2023

    Antimicrobial susceptibility testing (AST) is critical in modern medicine, helping doctors determine which antibiotics are most likely to be effective against particular bacterial infections. Across the globe, standards for AST primarily revolve around the European EUCAST and the American CLSI. Dr. Gunnar Kahlmeter, one of the main architects of EUCAST, offers unique insights into the…

  • Dr. Anne J. Gonzales-Luna: Progress in Pediatric Clostridioides difficile Infection丨ECCMID 2023a

    Clostridioides difficile, a primary cause of antibiotic-associated diarrhea, presents a spectrum of clinical manifestations. While less prevalent in children than adults, the incidence of pediatric Clostridioides difficile infection (CDI) is on the rise. The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) dedicated a session to shed light on this pressing issue,…